August 01, 2011 09:09 ET

Equity Research on Immucor Inc. and Celldex Therapeutics Inc. - Uncertainty for Diagnostic Substances Sector

NEW YORK, NY--(Marketwire - Aug 1, 2011) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Diagnostic Substances industry and are offering free analytical research on Immucor Inc. (NASDAQ: BLUD) and Celldex Therapeutics Inc. (NASDAQ: CLDX). Register with us today at to have free access to these research reports.

Several factors are creating uncertainty for the diagnostic substance sector. One major piece of news moving through the sector lately has been the announced acquisition of Immucor Inc. Immucor Inc. report is accessible for free by registering today at

Generally speaking, economic uncertainty has been hard on companies in the sector dealing in the blood markets. Several small donation centers have shut down and hospitals pared back their spending in the downturn. With the amount of adequately insured patients falling, demand has been hurt even further. Get your free reports on Immucor Inc. and Celldex Therapeutics Inc. at There is no commitment to join. is the Ultimate Trading Environment for investors. If you are considering owning Immucor Inc. and Celldex Therapeutics Inc. then you should sign up for a free membership and our complimentary reports today at Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

These factors weighed into the decision of Immucor Inc. to agree to be acquired by TPG Capital for $1.97 billion. The transaction, subject to regulatory considerations, will take place in the back half of the year.

With a great deal of unknowns looming on the horizon thanks to the health care reform, the Diagnostic Substances sector finds itself on uncertain ground. Investors will have to stay tuned in order to determine the futures of companies like Celldex Therapeutics Inc. Celldex Therapeutics Inc. report is accessible for free by registering today at

The two Diagnostic Substances stocks research reports are available for free by signing up now on


Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information